Skip to main content
medRxiv
  • Home
  • About
  • Submit
  • ALERTS / RSS
Advanced Search

Bayesian Adaptive Clinical Trials for Anti-Infective Therapeutics during Epidemic Outbreaks

Qingyang Xu, Shomesh Chaudhuri, Danying Xiao, Andrew W. Lo
doi: https://doi.org/10.1101/2020.04.09.20059634
Qingyang Xu
1MIT Operations Research Center, Cambridge, MA, USA
2MIT Laboratory for Financial Engineering, Cambridge, MA, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Shomesh Chaudhuri
3QLS Advisors, LLC, Cambridge, MA, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Danying Xiao
1MIT Operations Research Center, Cambridge, MA, USA
2MIT Laboratory for Financial Engineering, Cambridge, MA, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Andrew W. Lo
1MIT Operations Research Center, Cambridge, MA, USA
2MIT Laboratory for Financial Engineering, Cambridge, MA, USA
3QLS Advisors, LLC, Cambridge, MA, USA
4MIT Sloan School of Management, Cambridge, MA, USA
5MIT Computer Science and Artificial Intelligence Laboratory, Cambridge, MA, USA
6MIT Department of Electrical Engineering and Computer Science, Cambridge, MA, USA
7Santa Fe Institute, Santa Fe, NM, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: alo-admin@mit.edu
  • Abstract
  • Full Text
  • Info/History
  • Metrics
  • Data/Code
  • Preview PDF
Loading

Abstract

In the midst of epidemics such as COVID-19, therapeutic candidates are unlikely to be able to complete the usual multi-year clinical trial and regulatory approval process within the course of an outbreak. We apply a Bayesian adaptive patient-centered model—which minimizes the expected harm of false positives and false negatives—to optimize the clinical trial development path during such outbreaks. When the epidemic is more infectious and fatal, the Bayesian-optimal sample size in the clinical trial is lower and the optimal statistical significance level is higher. For COVID-19 (assuming a static R0 = 2 and initial infection percentage of 0.1%), the optimal significance level is 7.1% for a clinical trial of a non-vaccine anti-infective therapeutic clinical trial and 13.6% for that of a vaccine. For a dynamic R0 ranging from 2 to 4, the corresponding values are 14.4% and 26.4%, respectively. Our results illustrate the importance of adapting the clinical trial design and the regulatory approval process to the specific parameters and stage of the epidemic.

Competing Interest Statement

A.L. reports personal investments in private biotech companies, biotech venture capital funds, and mutual funds. A. L. is a co-founder and partner of QLS Advisors, a healthcare analytics company; an advisor to BrightEdge Ventures; an advisor to and investor in BridgeBio Pharma; a director of Roivant Sciences Ltd., and Annual Reviews; chairman emeritus and senior advisor to AlphaSimplex Group; and a member of the Board of Overseers at Beth Israel Deaconess Medical Center and the NIH’s National Center for Advancing Translational Sciences Advisory Council and Cures Acceleration Network Review Board. S.C. is a co-founder and partner of QLS Advisors, a healthcare analytics company.

Funding Statement

Research funding for this project was provided by the MIT Laboratory for Financial Engineering and its sponsors (listed at https://lfe.mit.edu/about/sponsors/). No funding bodies had any role in study design, data collection and analysis, decision to publish, or preparation of this manuscript. No direct funding was received for this study. The authors were personally salaried by their institutions during the period of writing (though no specific salary was set aside or given for the writing of this manuscript).

Author Declarations

All relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.

Yes

All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.

Yes

Footnotes

  • * We thank Murray Sheldon, Chi Heem Wong, the editor, associate editor, and reviewer for many helpful comments and suggestions, and Jayna Cummings for editorial assistance. Research support from the MIT Laboratory for Financial Engineering is gratefully acknowledged. The views and opinions expressed in this article are those of the authors only, and do not represent the views, policies, and opinions any institution or agency, any of their affiliates or employees, or any of the individuals acknowledged above.

Data Availability

All data used in this project are commercially available to other authors on the same terms.

https://informa.com

Copyright 
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY 4.0 International license.
Back to top
PreviousNext
Posted April 14, 2020.
Download PDF
Data/Code
Email

Thank you for your interest in spreading the word about medRxiv.

NOTE: Your email address is requested solely to identify you as the sender of this article.

Enter multiple addresses on separate lines or separate them with commas.
Bayesian Adaptive Clinical Trials for Anti-Infective Therapeutics during Epidemic Outbreaks
(Your Name) has forwarded a page to you from medRxiv
(Your Name) thought you would like to see this page from the medRxiv website.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Share
Bayesian Adaptive Clinical Trials for Anti-Infective Therapeutics during Epidemic Outbreaks
Qingyang Xu, Shomesh Chaudhuri, Danying Xiao, Andrew W. Lo
medRxiv 2020.04.09.20059634; doi: https://doi.org/10.1101/2020.04.09.20059634
Digg logo Reddit logo Twitter logo Facebook logo Google logo LinkedIn logo Mendeley logo
Citation Tools
Bayesian Adaptive Clinical Trials for Anti-Infective Therapeutics during Epidemic Outbreaks
Qingyang Xu, Shomesh Chaudhuri, Danying Xiao, Andrew W. Lo
medRxiv 2020.04.09.20059634; doi: https://doi.org/10.1101/2020.04.09.20059634

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Subject Area

  • Health Policy
Subject Areas
All Articles
  • Addiction Medicine (215)
  • Allergy and Immunology (495)
  • Anesthesia (106)
  • Cardiovascular Medicine (1093)
  • Dentistry and Oral Medicine (195)
  • Dermatology (141)
  • Emergency Medicine (274)
  • Endocrinology (including Diabetes Mellitus and Metabolic Disease) (499)
  • Epidemiology (9757)
  • Forensic Medicine (5)
  • Gastroenterology (480)
  • Genetic and Genomic Medicine (2303)
  • Geriatric Medicine (222)
  • Health Economics (462)
  • Health Informatics (1553)
  • Health Policy (732)
  • Health Systems and Quality Improvement (602)
  • Hematology (236)
  • HIV/AIDS (501)
  • Infectious Diseases (except HIV/AIDS) (11631)
  • Intensive Care and Critical Care Medicine (616)
  • Medical Education (236)
  • Medical Ethics (67)
  • Nephrology (256)
  • Neurology (2139)
  • Nursing (134)
  • Nutrition (335)
  • Obstetrics and Gynecology (426)
  • Occupational and Environmental Health (517)
  • Oncology (1172)
  • Ophthalmology (363)
  • Orthopedics (128)
  • Otolaryngology (220)
  • Pain Medicine (145)
  • Palliative Medicine (50)
  • Pathology (309)
  • Pediatrics (694)
  • Pharmacology and Therapeutics (298)
  • Primary Care Research (265)
  • Psychiatry and Clinical Psychology (2172)
  • Public and Global Health (4645)
  • Radiology and Imaging (775)
  • Rehabilitation Medicine and Physical Therapy (455)
  • Respiratory Medicine (623)
  • Rheumatology (274)
  • Sexual and Reproductive Health (225)
  • Sports Medicine (208)
  • Surgery (250)
  • Toxicology (43)
  • Transplantation (120)
  • Urology (94)